- Home
- CRWD vs NVO Comparison
CRWD vs NVO Comparison
Compare CRWD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | NVO |
|---|---|---|
| Founded | 2011 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3B | 197.4B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRWD | NVO |
|---|---|---|
| Price | $694.80 | $47.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 48 | 11 |
| Target Price | ★ $507.00 | $51.00 |
| AVG Volume (30 Days) | 3.2M | ★ 11.9M |
| Earning Date | 06-02-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $4,812,005,000.00 | N/A |
| Revenue This Year | $24.85 | N/A |
| Revenue Next Year | $21.40 | $3.70 |
| P/E Ratio | $6,165.82 | ★ $13.60 |
| Revenue Growth | ★ 21.71 | N/A |
| 52 Week Low | $342.72 | $35.12 |
| 52 Week High | $785.66 | $71.80 |
Technical Indicators
Market Signals| Indicator | CRWD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 65.41 |
| Support Level | $463.35 | $47.52 |
| Resistance Level | $785.66 | $47.79 |
| Average True Range (ATR) | 31.68 | 1.32 |
| MACD | -7.46 | 0.47 |
| Stochastic Oscillator | 81.82 | 87.39 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.